CN101569728B - Pharmaceutical composition for treating urticaria - Google Patents
Pharmaceutical composition for treating urticaria Download PDFInfo
- Publication number
- CN101569728B CN101569728B CN2008101056969A CN200810105696A CN101569728B CN 101569728 B CN101569728 B CN 101569728B CN 2008101056969 A CN2008101056969 A CN 2008101056969A CN 200810105696 A CN200810105696 A CN 200810105696A CN 101569728 B CN101569728 B CN 101569728B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- radix
- weight
- urticaria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating urticaria, which consists of rhubarb, giant knotweed rhizome, amur corktree bark, stemona root, danshen root and zaocys dhumnade. The pharmaceutical composition has the efficacies of eliminating dampness and heat, expelling wind and cold pathogens, expelling wind and relieving itching, removing heat from the blood and harmonizing the stomach, releasing toxin and promoting bowel movements, harmonizing the nutrient and defense, and invigorating qi and nourishing blood to tonify the liver and the kidney, achieves adjusting the in vivo immunologic function, has remarkable curative effect of treating the urticaria dermatosis, can cure the urticaria dermatosis in a short period, has no toxic side effects and no recrudescence.
Description
Technical field
The present invention relates to the urticarial pharmaceutical composition of a kind of treatment.
Background technology
Nettle rash is a kind of common anaphylaxis dermatosis; When contact allergy is former, can be at the not specific position of health, the red patch block-shaped, not of uniform size of emerging; These produce the position of patch; Situation that can itch, if it is former and treat not stop contact allergy, the situation that eruption is itched will be aggravated.Use at present Western medicine, like medicines such as hismanal, clarityne, quick enlightening treatment urticaria dermatosis, though certain curative effect is arranged, cure rate is low, and dependency is big, and taking Western medicine indefinitely has certain side effect to human body, and can not thoroughly effect a radical cure.
Summary of the invention
The object of the present invention is to provide the urticarial pharmaceutical composition of a kind of treatment.
The present invention realizes through following technical scheme:
The crude drug of pharmaceutical composition of the present invention consists of:
Radix Et Rhizoma Rhei 1-3 weight portion Rhizoma Polygoni Cuspidati 1-3 weight portion Cortex Phellodendri 1-3 weight portion
Radix Stemonae 0.5-1.5 weight portion Radix Salviae Miltiorrhizae 0.5-1.5 weight portion Zaocys 1-3 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Radix Et Rhizoma Rhei 2 weight portion Rhizoma Polygoni Cuspidati 2 weight portion Cortex Phellodendris 2 weight portions
The Radix Stemonae 1 weight portion Radix Salviae Miltiorrhizae 1 weight portion Zaocys 2 weight portions
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Radix Et Rhizoma Rhei 1.5 weight portion Rhizoma Polygoni Cuspidati 2.5 weight portion Cortex Phellodendris 1.5 weight portions
The Radix Stemonae 1.3 weight portion Radix Salviae Miltiorrhizaes 0.7 weight portion Zaocys 2.5 weight portions
The optimum ratio of pharmaceutical composition of the present invention is:
Radix Et Rhizoma Rhei 2.5 weight portion Rhizoma Polygoni Cuspidati 1.5 weight portion Cortex Phellodendris 2.5 weight portions
The Radix Stemonae 0.7 weight portion Radix Salviae Miltiorrhizae 1.5 weight portion Zaocyss 1.5 weight portions
Pharmaceutical composition of the present invention adds conventional adjuvant and processes the capsule of clinical acceptance, tablet, granule, pill, powder, decoction, oral liquid, injection or lyophilized injectable powder.
Pharmaceutical composition of the present invention has that eliminating damp-heat, expelling wind and cold, dispelling wind are antipruritic, removing heat from blood stomach function regulating, detoxifcation relieving constipation, Zhou Heying are defended, the effect of benefiting QI and nourishing blood invigorating the liver and kidney; Reach immunologic function in the adjustment body; Urticarial treatment there is significant curative effect; Can cure urticaria in a short time,, not recur the human non-toxic side effect.
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
Experimental example: medicine composite for curing of the present invention is treated 180 routine urticaria patients' clinical observation material
1, clinical data:
1.1 physical data:
180 routine urticaria patients all are the outpatient, wherein male 110 examples, women 70 examples; The oldest 66 years old, minimum 12 years old; The course of disease is the longest 20 years, and is the shortest 1 year.
1.2 diagnostic criteria:
The Western medicine diagnose standard: skin lesion is a welt, and the flushing speckle plays delitescence suddenly, leaves no trace after disappearing; Minority can be with whole body or systemic symptom, conscious pruritus.
The tcm diagnosis standard: the rubella wheal that differs in size, cerise be or/and pale asphyxia, acute pruritus, and every manyly take place suddenly disappeared rapidly, leaves no trace after more.
2, Therapeutic Method:
Medicine is formed: Radix Et Rhizoma Rhei 2g, Rhizoma Polygoni Cuspidati 2g, Cortex Phellodendri 2g, Radix Stemonae 1g, Radix Salviae Miltiorrhizae 1g, Zaocys 2g.
Method for preparing: get the above-mentioned raw materials medicine, pulverize, dress " 0 " number capsule, every 0.4g.
Instructions of taking: each 6, every day 3 times.
3, criterion of therapeutical effect
Produce effects: welt disappears, and does not itch, and in the drug withdrawal 3 days, does not have recurrence;
Effectively: welt reduces, and gargalesthesia and General Symptoms alleviate;
Invalid: welt rises one after another, and does not reduce.
4, therapeutic outcome (seeing the following form)
5, model case
Case 1: the big Wei Cun in Fanyu District Da Shi town, Guangzhou, Lee * *, man 30 years old, peasant, first visit on April 6 in 2001; The buttocks chronic eczema is plump, and coarse, drying, pruritus, disease are more than 6 years; Often outbreak is repeatedly sought medical advice for many years and is not healed, and through taking " skin recovering capsule " 6 weeks, follows up a case by regular visits to, and fully recovers at present.
Case 2: the Hong-Kong general washes the bright institute of open grave, Ruan * *, 68 years old, the man; The resident, first visit on May 17 in 2004, the coarse tuberosity pigmentation of two lower limb shank face tables desquamation, pruritus is unbearably; Disease is sent out more than 20 year, through failing to respond to any medical treatment for many years, and outbreak repeatedly; After come the diagnosis and treatment patient of healing to introduce and see a doctor, take " skin recovering capsule " 2 wheat harvesting periods, follow up a case by regular visits at present rehabilitation and do not have recurrence.
Following embodiment all can realize the effect of above-mentioned experimental example.
The specific embodiment
Embodiment 1: capsule
Radix Et Rhizoma Rhei 2kg Rhizoma Polygoni Cuspidati 2kg Cortex Phellodendri 2kg
Radix Stemonae 1kg Radix Salviae Miltiorrhizae 1kg Zaocys 2kg
Get the above-mentioned raw materials medicine, pulverize, dress " 0 " number capsule, every 0.4g, each 6, every day 3 times.
Embodiment 2: tablet
Radix Et Rhizoma Rhei 1.5kg Rhizoma Polygoni Cuspidati 2.5kg Cortex Phellodendri 1.5kg
Radix Stemonae 1.3kg Radix Salviae Miltiorrhizae 0.7kg Zaocys 2.5kg
Said medicine adds conventional adjuvant by common process and processes tablet.
Embodiment 3: granule
Radix Et Rhizoma Rhei 2.5kg Rhizoma Polygoni Cuspidati 1.5kg Cortex Phellodendri 2.5kg
Radix Stemonae 0.7kg Radix Salviae Miltiorrhizae 1.5kg Zaocys 1.5kg
Said medicine adds conventional adjuvant by common process and processes granule.
Embodiment 4: pill
Radix Et Rhizoma Rhei 2kg Rhizoma Polygoni Cuspidati 2kg Cortex Phellodendri 2kg
Radix Stemonae 1kg Radix Salviae Miltiorrhizae 1kg Zaocys 2kg
Said medicine adds conventional adjuvant by common process and processes pill.
Embodiment 5: oral liquid
Radix Et Rhizoma Rhei 2.5kg Rhizoma Polygoni Cuspidati 1.5kg Cortex Phellodendri 2.5kg
Radix Stemonae 0.7kg Radix Salviae Miltiorrhizae 1.5kg Zaocys 1.5kg
Said medicine adds conventional adjuvant by common process and processes oral liquid.
Claims (6)
1. treat urticarial pharmaceutical composition for one kind, it is characterized in that the crude drug of this pharmaceutical composition consists of:
Radix Et Rhizoma Rhei 1-3 weight portion Rhizoma Polygoni Cuspidati 1-3 weight portion Cortex Phellodendri 1-3 weight portion
Radix Stemonae 0.5-1.5 weight portion Radix Salviae Miltiorrhizae 0.5-1.5 weight portion Zaocys 1-3 weight portion.
2. pharmaceutical composition as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Radix Et Rhizoma Rhei 2 weight portion Rhizoma Polygoni Cuspidati 2 weight portion Cortex Phellodendris 2 weight portions
The Radix Stemonae 1 weight portion Radix Salviae Miltiorrhizae 1 weight portion Zaocys 2 weight portions.
3. pharmaceutical composition as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Radix Et Rhizoma Rhei 1.5 weight portion Rhizoma Polygoni Cuspidati 2.5 weight portion Cortex Phellodendris 1.5 weight portions
The Radix Stemonae 1.3 weight portion Radix Salviae Miltiorrhizaes 0.7 weight portion Zaocys 2.5 weight portions.
4. pharmaceutical composition as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Radix Et Rhizoma Rhei 2.5 weight portion Rhizoma Polygoni Cuspidati 1.5 weight portion Cortex Phellodendris 2.5 weight portions
The Radix Stemonae 0.7 weight portion Radix Salviae Miltiorrhizae 1.5 weight portion Zaocyss 1.5 weight portions.
5. like the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that the conventional adjuvant that this pharmaceutical composition adds pharmaceutically processes capsule, tablet, granule, pill, powder, decoction, oral liquid, injection or the lyophilized injectable powder of clinical acceptance.
6. like the application of the arbitrary described pharmaceutical composition of claim 1-4 in the urticarial medicine of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101056969A CN101569728B (en) | 2008-05-04 | 2008-05-04 | Pharmaceutical composition for treating urticaria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101056969A CN101569728B (en) | 2008-05-04 | 2008-05-04 | Pharmaceutical composition for treating urticaria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101569728A CN101569728A (en) | 2009-11-04 |
| CN101569728B true CN101569728B (en) | 2012-04-25 |
Family
ID=41229297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101056969A Expired - Fee Related CN101569728B (en) | 2008-05-04 | 2008-05-04 | Pharmaceutical composition for treating urticaria |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101569728B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1524548A (en) * | 2003-02-27 | 2004-09-01 | 白汝实 | Liquid traditional Chinese medicine for treating skin disease and its preparation process |
| CN1768812A (en) * | 2005-10-24 | 2006-05-10 | 高欲林 | Medicinal composition for removing dampness to relieve itching and its preparation method and uses |
| CN101028422A (en) * | 2007-04-16 | 2007-09-05 | 北京艺信堂医药研究所 | Chinese-medicinal decoction for treating hives |
-
2008
- 2008-05-04 CN CN2008101056969A patent/CN101569728B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1524548A (en) * | 2003-02-27 | 2004-09-01 | 白汝实 | Liquid traditional Chinese medicine for treating skin disease and its preparation process |
| CN1768812A (en) * | 2005-10-24 | 2006-05-10 | 高欲林 | Medicinal composition for removing dampness to relieve itching and its preparation method and uses |
| CN101028422A (en) * | 2007-04-16 | 2007-09-05 | 北京艺信堂医药研究所 | Chinese-medicinal decoction for treating hives |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101569728A (en) | 2009-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102309644B (en) | Traditional Chinese medical composition for treating bone fracture | |
| CN102091202B (en) | Traditional Chinese medicinal composition for treating fracture and preparation method thereof | |
| CN101496860B (en) | Chinese patent medicine for treating fracture | |
| CN104523872A (en) | Traditional Chinese medicine combination for treating rheumatic arthritis and preparation method thereof | |
| CN101569728B (en) | Pharmaceutical composition for treating urticaria | |
| CN103463304B (en) | One treats arthroncus of knee Chinese medicine | |
| CN102441131A (en) | Chinese medicinal composition for treating traumatic injury | |
| CN100566741C (en) | A kind of antipsoriatics thing | |
| CN105381168B (en) | A kind of Yaotongning medicine and preparation method thereof | |
| CN104147562A (en) | Traditional Chinese medicine (TCM) for treating chronic pelvic inflammatory diseases caused by congealing cold-damp | |
| CN103816505A (en) | Medicine for treating disease of prostate | |
| CN103735956A (en) | Medicine for treating cervical cancer | |
| CN103784574B (en) | A kind of Chinese medicine for oral administration preventing and treating hemolytic disease of newborn | |
| CN108785421A (en) | A kind of Chinese medicine preparation and its preparation method for treating fracture | |
| CN101961393B (en) | Chinese medicinal composition for treating haemorrhoids and preparation method thereof | |
| CN102198244B (en) | Medicament for treating gastric and duodenal ulcers, gastritis and other diseases and preparation method thereof | |
| CN105148139A (en) | Traditional Chinese medicine for treating cervical cancer | |
| CN101732408B (en) | Chinese medicament for treating angitis and limb angiopathy and preparation method thereof | |
| CN104257931A (en) | Orthopedic traumatic injury external application patch and preparation method thereof | |
| CN103566025B (en) | Traditional Chinese medicine for treating irregular menstrual period | |
| CN104721488A (en) | Traditional Chinese medicine for treating ascariasis | |
| CN103006857A (en) | Medicinal composition for treating scapulohumeral periarthritis | |
| CN106421181A (en) | Osteomyelitis powder cream | |
| CN105641635A (en) | Ointment for treating lumbar intervertebral disc protrusion | |
| CN103585567A (en) | Traditional Chinese medicine composition for treating gall-stone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20150504 |
|
| EXPY | Termination of patent right or utility model |